Risk Factor Analysis for Coronary Atherosclerosis Measured by MDCT

October 12, 2015 updated by: Kyung Mook Choi, Korea University
Coronary MDCT (multi-detector computed tomography) has been useful screening imaging modality for the coronary artery disease. Recently, novel adipokines and hepatokines as well as various inflammatory markers have been known as direct regulators of atherosclerosis. Therefore, the investigators examine the correlation of various metabolic risk factors including adipokines and hepatokines with coronary atherosclerosis measured by coronary MDCT in apparently healthy people.

Study Overview

Status

Completed

Study Type

Observational

Enrollment (Actual)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Apparently healthy people who underwent medical routine check up in Korea Helath Promotion Center.

Description

Inclusion Criteria:

  • Apparently healthy people who underwent medical routine check up in Korea Health Promotion Center.
  • age > 20 years

Exclusion Criteria:

  • History of cardiovascular disease (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization)
  • Diabetes
  • Stage 2 hypertension
  • Severe renal or hepatic disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Healthy people

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
relation of adipokines and hepatokines with coronary atherosclerosis measured by MDCT
Time Frame: 3month
to examine the correlation of serum concentration of various adipokine such as adiponectin, resistin, A-FABP with coronary atheroslcerosis measured by MDCT as AGATSTON score, modified Gensini score
3month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
relation of adipokines and hepatokines with coronary atherosclerosis measured by MDCT
Time Frame: 3months
to examine the correlation of serum concentration of various hepatokines such as FGF-21, fetuin- A and selenoprotein P with coronary atheroslcerosis measured by MDCT as AGATSTON score, modified Gensini score
3months
the correlation of various inflammatory markers with coronary atherosclerosis
Time Frame: 3months
3months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2012

Primary Completion (Actual)

August 1, 2012

Study Registration Dates

First Submitted

April 24, 2012

First Submitted That Met QC Criteria

April 28, 2012

First Posted (Estimate)

May 1, 2012

Study Record Updates

Last Update Posted (Estimate)

October 14, 2015

Last Update Submitted That Met QC Criteria

October 12, 2015

Last Verified

April 1, 2012

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Atherosclerosis

3
Subscribe